Related Experiment Video

Updated: Jun 14, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Effect of atorvastatin on cellular adhesion molecules on leukocytes in patients with normocholesterolemic coronary

Thomas Walter1, Tim Suselbeck, Martin Borggrefe

  • 1University Medical Centre Mannheim, First Department of Medicine, D-68167 Mannheim, Germany. thomas.walter.med@umm.de

In Vivo (Athens, Greece)
|April 6, 2010
PubMed

Insights

Atorvastatin therapy significantly reduced the expression of key cellular adhesion molecules (CD40L, CD11b, CD54) on leukocytes in patients with coronary artery disease (CAD). This suggests atorvastatin may improve chronic inflammation and hemostasis.

Area of Science:

  • Cardiovascular Medicine
  • Immunology
  • Pharmacology

Background:

  • Cellular adhesion molecules on leukocytes are crucial in coronary artery disease (CAD).
  • Normocholesterolemic CAD patients were studied to isolate the effects of atorvastatin.
  • Understanding leukocyte adhesion molecule expression is vital for CAD management.

Purpose of the Study:

  • To evaluate the impact of atorvastatin therapy on leukocyte cellular adhesion molecule expression in normocholesterolemic CAD patients.
  • To determine if atorvastatin influences specific adhesion molecules like CD40L, CD11a, CD11b, CD54, CD62L, and CD41.
  • To explore potential mechanisms by which atorvastatin affects CAD progression.

Main Methods:

  • A comparative study involving 54 CAD patients on atorvastatin and 54 CAD patients without atorvastatin.
  • Flow cytometry was used to measure the expression of CD40L, CD11a, CD11b, CD54, CD62L, and CD41 on leukocytes.
  • All participants maintained normal cholesterol levels (normocholesterolemic).

Main Results:

  • Atorvastatin treatment significantly decreased CD40L, CD11b, and CD54 expression on monocytes and neutrophils.
  • A significant reduction in CD11a expression on monocytes was observed in the atorvastatin group.
  • These findings highlight a direct impact of atorvastatin on leukocyte adhesion molecule profiles.

Conclusions:

  • Atorvastatin therapy appears to mitigate chronic inflammation in CAD patients.
  • The reduction in cellular adhesion molecules suggests a potential beneficial effect of atorvastatin on hemostasis.
  • Further research can explore the clinical implications of these molecular changes in CAD management.
Abstract

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Quantitation of Endothelial Cell Adhesiveness In Vitro10:24

Quantitation of Endothelial Cell Adhesiveness In Vitro

Published on: June 18, 2015

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...